Guy Macdonald
CIK 1296998 · President and Chief Executive · last filed 2025-06-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$35.4K
Companies
3
Total Filings
65
Lifetime Open-Market Net
-$7.67M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCYX | Director | 9,750 | $3.63 | $35.4K | $145.6K | 33 | 2025-06-30 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | President and Chief Executive | 0 | — | — | -$7.82M | 30 | 2020-07-29 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Executive VP, Operations | — | — | — | $0 | 2 | 2007-06-04 |
Recent Filings · Page 2 of 7
65 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-09 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −7,605 | -$17.3K | EDGAR |
| 2019-06-20 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2019-01-18 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | +5,390 | $0 | EDGAR |
| 2019-01-04 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2018-10-03 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2018-07-03 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2018-04-04 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-04-04 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2018-01-19 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Grant (A) | +4,667 | $0 | EDGAR |
| 2018-01-04 | SCYX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.